DengueNCT07838701
Efficacy and Safety of Indoor Residual Spray for Dengue Vector Control
A study testing Indoor residual spray with Deltamethrin 2.5% WP in people with Dengue, run by Pak Emirates Military Hospital at 1 site in Pakistan.
Trial summary
This quasi-experimental interventional study was conducted over 1 year, from May 2024-May 2025 at Station Health Organization, Combined Military Hospital, Peshawar Cantonment. Two comparable localities in Peshawar Cantonment were selected based on previous dengue incidence reports. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Dengue
- What is being tested?
- Indoor residual spray with Deltamethrin 2.5% WP
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 sitePakistan
- Study dates
- 1 May 2024to 1 May 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Households consenting to participate and allow entomological inspections.
- Permanent residents with no history of shifting during the study period.
Who cannot join
- Houses under construction or vacant.
- If any resident of the household had prior history of allergic reaction to the sprayed chemicals.
Trial locations and contacts
1 site in 1 country.
Pakistan1 site
Station Health Organization C/O Combined Military Hospital Peshawar
Peshawar, Khyber Pakhtunkhwa, 25000
About this study
This quasi-experimental interventional study was conducted over 1 year, from May 2024-May 2025 at Station Health Organization, Combined Military Hospital, Peshawar Cantonment. Two comparable localities in Peshawar Cantonment were selected based on previous dengue incidence reports. Non-Probability consecutive sampling technique was used. Prior approval was sought from Station Commander, Station Headquarters Peshawar to conduct the study in Peshawar Cantonment. Hospital ethical review certificate was obtained (vide CMH Peshawar Letter No: 00254/25). Written informed consent was taken from the participants for inclusion in the study. One locality was designated as the intervention area (Indoor Residual Spray applied), and the other as the control area (Indoor Residual Spray not applied). Households were selected using a non-probability consecutive sampling technique.
In the intervention area, indoor residual spraying was conducted using Deltamethrin 2.5% WP, following WHO guidelines. Spray teams were trained and monitored to ensure proper application on interior walls, dark corners, and mosquito resting sites. Spraying was repeated every three months.
Read more
Entomological surveys were conducted at baseline and monthly thereafter in both areas, using larval/pupal indices (House Index and Breteau Index). Adult mosquito density was measured using backpack aspirators and resting catches. Dengue case data was collected by the Station Health Organization from CMH Peshawar and cross-checked with the Pathology department of the same hospital. The study was conducted as pilot study of the organization.
Data was analyzed using Statistical Pacakage for Social Sceinces version 27. Mean mosquito density, larval indices, and dengue incidence were compared between intervention and control areas using paired t-test. A p-value < 0.05 was considered statistically significant.
- Conditions
- Dengue
- Being tested
- Indoor residual spray with Deltamethrin 2.5% WP
- Keywords
- Dengue, Vector Control, Mosquito
- Medical subject headings
- Dengue
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Indoor residual spray with Deltamethrin 2.5% WPDrug
In the intervention area, indoor residual spraying was conducted using Deltamethrin 2.5% WP, following WHO guidelines. Spray teams were trained and monitored to ensure proper application on interior walls, dark corners, and mosquito resting sites. Spraying was repeated every three months.
| Study group | Role | What they receive |
|---|---|---|
| IRS Area | Experimental | 100 households were inducted in the IRS Arms Receives: Drug: Indoor residual spray with Deltamethrin 2.5% WP |
| Control Area | No intervention | 100 households were inducted in the Control Arm |
What is being measured
The primary outcome is the main question the study is designed to answer.
To assess the safety of indoor residual spray in terms of participants reported adverse side effects after the use of spray ; both immediate and up to 3 months folllow up
To assess the safety of indoor residual spray in terms of participants reported adverse side effects after the use of spray ; both immediate and up to 3 months folllow up. Patients will report any adverse effects to the investigator, including rhinitis, skin rash, urticaria or any other newer finding noticed by the participant.
Measured: 3 months follow up to asses the safety of indoor residual spray
To assess the efficacy of indoor residual spray using House Index
The Efficacy of indoor residual spray was assessed using House Index. House Index was compared for interventional area where the indoor residual spray was performed and the control area which was intervention naive. The baseline and 3 months follow up indices were compared to ascertain the efficacy of intervention. The House Index (HI) is the percentage of inspected houses that have mosquito larvae or pupae in or around them
Measured: 3 months follow-up to assess the efficacy of indoor residual spray to kill the mosquitoes using changes in House Index.
The Efficacy of indoor residual spray was assessed using Bretau Index.
The Efficacy of indoor residual spray was assessed using Bretau Index. Bretau Index was compared for interventional area where the indoor residual spray was performed and the control area which was intervention naive. Bretau Index measures mosquito vector density by tracking the number of positive water-holding containers per 100 houses inspected
Measured: The baseline and 3-month follow-up indices were compared to ascertain the efficacy of intervention.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2026
- Study start1 May 2024
- Primary completion1 May 2025
- Study completion1 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for DengueStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- it was a quasi experimental stud
- Masking
- None (open label)
- Enrolment
- 200 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pak Emirates Military Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Taimoor Ashraf Khan, Pak Emirates Military Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07838701
- Sponsor's protocol ID
- 00254/25
- Status last verified
- Sep 2026
- First submitted
- 6 Sep 2026
- Last updated
- 24 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Study protocol and statistical data analysis sheet/ methods will be shraed upon request
Publications
Bowman LR, Donegan S, McCall PJ. Is Dengue Vector Control Deficient in Effectiveness or Evidence?: Systematic Review and Meta-analysis. PLoS Negl Trop Dis. 2016 Mar 17;10(3):e0004551. doi: 10.1371/journal.pntd.0004551. eCollection 2016 Mar.
PubMed 26986468Gubler DJ. The global emergence/resurgence of arboviral diseases as public health problems. Arch Med Res. 2002 Jul-Aug;33(4):330-42. doi: 10.1016/s0188-4409(02)00378-8.
PubMed 12234522
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of Indoor Residual Spray for Dengue Vector Control
- ClinicalTrials.gov ID
- NCT07838701
- Acronym / sponsor ID
- 00254/25
- Conditions
- Dengue
- Keywords
- Dengue, Vector Control, Mosquito
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 200 participants (actual)
- Lead sponsor
- Pak Emirates Military HospitalUniversity, hospital or other
- Study start
- 1 May 2024 (actual)
- Primary completion
- 1 May 2025 (actual)
- Study completion
- 1 May 2025 (actual)
- First posted
- 24 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This quasi-experimental interventional study was conducted over 1 year, from May 2024-May 2025 at Station Health Organization, Combined Military Hospital, Peshawar Cantonment. Two comparable localities in Peshawar Cantonment were selected based on previous dengue incidence reports. Non-Probability consecutive sampling technique was used. Prior approval was sought from Station Commander, Station Headquarters Peshawar to conduct the study in Peshawar Cantonment. Hospital ethical review certificate was obtained (vide CMH Peshawar Letter No: 00254/25). Written informed consent was taken from the participants for inclusion in the study. One locality was designated as the intervention area (Indoor Residual Spray applied), and the other as the control area (Indoor Residual Spray not applied). Households were selected using a non-probability consecutive sampling technique.
In the intervention area, indoor residual spraying was conducted using Deltamethrin 2.5% WP, following WHO guidelines. Spray teams were trained and monitored to ensure proper application on interior walls, dark corners, and mosquito resting sites. Spraying was repeated every three months.
Entomological surveys were conducted at baseline and monthly thereafter in both areas, using larval/pupal indices (House Index and Breteau Index). Adult mosquito density was measured using backpack aspirators and resting catches. Dengue case data was collected by the Station Health Organization from CMH Peshawar and cross-checked with the Pathology department of the same hospital. The study was conducted as pilot study of the organization.
Data was analyzed using Statistical Pacakage for Social Sceinces version 27. Mean mosquito density, larval indices, and dengue incidence were compared between intervention and control areas using paired t-test. A p-value < 0.05 was considered statistically significant.
Study design
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- it was a quasi experimental stud
| Arm | Type | Receives |
|---|---|---|
| IRS Area | Experimental | Drug: Indoor residual spray with Deltamethrin 2.5% WP100 households were inducted in the IRS Arms |
| Control Area | No intervention | –100 households were inducted in the Control Arm |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Households consenting to participate and allow entomological inspections.
- Permanent residents with no history of shifting during the study period.
Key exclusion criteria (2 listed)
- Houses under construction or vacant.
- If any resident of the household had prior history of allergic reaction to the sprayed chemicals.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Indoor residual spray with Deltamethrin 2.5% WPIn the intervention area, indoor residual spraying was conducted using Deltamethrin 2.5% WP, following WHO guidelines. Spray teams were trained and monitored to ensure proper application on interior walls, dark corners, and mosquito resting sites. Spraying was repeated every three months. | Drug | IRS Area |
Primary outcome
To assess the safety of indoor residual spray in terms of participants reported adverse side effects after the use of spray ; both immediate and up to 3 months folllow up
Time frame: 3 months follow up to asses the safety of indoor residual spray
To assess the safety of indoor residual spray in terms of participants reported adverse side effects after the use of spray ; both immediate and up to 3 months folllow up. Patients will report any adverse effects to the investigator, including rhinitis, skin rash, urticaria or any other newer finding noticed by the participant.
To assess the efficacy of indoor residual spray using House Index
Time frame: 3 months follow-up to assess the efficacy of indoor residual spray to kill the mosquitoes using changes in House Index.
The Efficacy of indoor residual spray was assessed using House Index. House Index was compared for interventional area where the indoor residual spray was performed and the control area which was intervention naive. The baseline and 3 months follow up indices were compared to ascertain the efficacy of intervention. The House Index (HI) is the percentage of inspected houses that have mosquito larvae or pupae in or around them
The Efficacy of indoor residual spray was assessed using Bretau Index.
Time frame: The baseline and 3-month follow-up indices were compared to ascertain the efficacy of intervention.
The Efficacy of indoor residual spray was assessed using Bretau Index. Bretau Index was compared for interventional area where the indoor residual spray was performed and the control area which was intervention naive. Bretau Index measures mosquito vector density by tracking the number of positive water-holding containers per 100 houses inspected
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2026.
- Background: PubMed 26986468Bowman LR, Donegan S, McCall PJ. Is Dengue Vector Control Deficient in Effectiveness or Evidence?: Systematic Review and Meta-analysis. PLoS Negl Trop Dis. 2016 Mar 17;10(3):e0004551. doi: 10.1371/journal.pntd.0004551. eCollection 2016 Mar.
- Background: PubMed 12234522Gubler DJ. The global emergence/resurgence of arboviral diseases as public health problems. Arch Med Res. 2002 Jul-Aug;33(4):330-42. doi: 10.1016/s0188-4409(02)00378-8.
- Individual participant dataSharing planned: Yes. Study protocol and statistical data analysis sheet/ methods will be shraed upon request
Related trials for Dengue
Active, not recruitingPhase 3
A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1)
Healthy
RecruitingPhase 1
Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection
Healthy Volunteers, Dengue
Active, not recruiting
A Controlled Human Infection Model of Dengue
Dengue
RecruitingPhase 2/3
Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative)
Dengue
RecruitingPhase 2
Adaptive Dengue Antiviral Platform Trial
Dengue, Antiviral Drugs
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Indoor residual spray with Deltamethrin 2.5% WP in people with Dengue, run by Pak Emirates Military Hospital at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To assess the safety of indoor residual spray in terms of participants reported adverse side effects after the use of spray ; both immediate and up to 3 months folllow up (time frame: 3 months follow up to asses the safety of indoor residual spray). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07838701, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2026.